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Congenital CMV infection (cCMV) is the most common congenital infection causing 
permanent long-term impairments (LTI). cCMV immunopathogenesis is largely unknown 
due to the complex interplay between viral, maternal, placental, and child factors. In this 
study, a large retrospective nationwide cohort of children with cCMV and their mothers 
was used. HLA-C, HLA-E, and HLA-G were assessed in 96 mother–child pairs in relation 
to symptoms at birth and LTI at 6 years of age. The mothers were additionally typed for 
killer cell immunoglobulin-like receptors. The maternal HLA-G 14 bp deletion/deletion 
polymorphism was associated with a worse outcome, as the immunomodulation effect 
of higher protein levels may induce less CMV control, with a direct impact on placenta 
and fetus. The absence of maternal HLA-C belonging to the C2 group was associated 
with symptoms at birth, as activating signals on decidual NK may override inhibitory 
signals, contributing to a placental pro-inflammatory environment. Here, the increased 
HLA-E*0101 and HLA-C mismatches, which were associated with symptoms at birth, 
may enhance maternal allo-reactivity to fetal Ags, and cause suboptimal viral clearance. 
Finally, HLA-C non-inherited maternal antigens (NIMAs) were associated with LTI. The 
tolerance induced in the fetus toward NIMAs may indirectly induce a suboptimal CMV 
antiviral response throughout childhood. In light of our findings, the potential role of 
maternal–child HLA in controlling CMV infection and cCMV-related disease, and the 
clinical value as predictor for long-term outcome certainly deserve further evaluation.
Keywords: mother–child hla, congenital cMV infection, immunopathology, allo-reactivity, suboptimal viral 
clearance, niMa effect, dried blood spots, biomarkers
inTrODUcTiOn
Human CMV is one of the most common causes of congenital viral infection, leading to a significant 
number of children with hearing loss and neurodevelopmental delay. The overall birth prevalence 
of congenital CMV infection (cCMV) in industrialized countries lies between 0.6 and 0.7% (1, 2). 
Among the congenitally infected infants, 12.7% are estimated to have symptoms at birth including 
Abbreviations: cCMV, congenital CMV infection; LTI, long-term impairments; dNK, decidual natural killer cells; DBS, dried 
blood spots; mm, mismatches; NIMAs, non-inherited maternal antigens; IPA, inherited paternal antigen; Ags, Antigens; 
HLA-G deletion, HLA-G del/del; sHLA-G, soluble HLA-G.
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petechiae, jaundice, hepatosplenomegaly, thrombocytopenia, 
chorioretinitis, and microcephaly (1, 2). An estimated 40–58% of 
these symptomatic children will develop long-term impairments 
(LTI), such as hearing loss, cognitive, and motor developmental 
delay (1). Of the 87.3% asymptomatic infants, around 13.5% will 
also develop LTI (1). Despite the current insights into the clinical 
outcome of cCMV, the multifactorial process that determines 
whether a child will be symptomatic at birth or will develop LTI 
is still poorly understood.
The vertical transmission rate is higher among women without 
prior CMV infection than among previously exposed women, 
suggesting a role for maternal immunity in the risk of vertical 
transmission (2). Vertical transmission takes place via placental 
infection. Once CMV infects the placenta, the extensive local 
damage and inflammation lead to placental dysfunction, which 
in turn can impair fetal development (3). The clinical impact of 
fetal infection is largely determined by vertical transmission in 
the first 20 weeks of pregnancy, during which the fetal immune 
system is still developing (4, 5). Importantly, the fetal and neonatal 
immune system may also play a role in controlling the infection, 
thereby influencing LTI development (6). A persistent productive 
infection may lead to late-onset or progression of sensorineural 
hearing loss, even though a role of immunopathology cannot be 
entirely excluded (7, 8). Hence, clinical outcome is the result of 
a multifactorial process that comprises maternal, placental, fetal, 
and child factors.
Pregnancy is considered a semi-allograft, in that the fetus may 
have HLA antigens (Ags) that the mother does not have. At the 
maternal–fetal interface, the majority of trophoblast cells are in 
direct contact with maternal cells, and several mechanisms are in 
place to prevent rejection of the fetal semi-allograft. Extravillous 
trophoblast cells do not express HLA-A, -B, -DR, -DQ, and -DP 
(9), but they do express HLA-C and the non-classical HLA-E and 
HLA-G. HLA-C and HLA-E prevent maternal NK cell-mediated 
cytotoxicity through binding with killer cell immunoglobulin-
like receptors (KIRs) expressed on decidual NK  cells (dNK). 
dNK  cells are the most abundant leukocyte population in the 
placenta (9), therefore, they play a fundamental role in pregnancy. 
KIR genotypes can be distinguished into two haplotypes. The 
KIR-A haplotype mainly contains inhibitory receptors, such as 
KIR2DL1, whereas the KIR-B haplotype also contains one or more 
activating receptors, such as KIR2DS1 (10, 11). NK cytotoxicity 
is controlled through a balance of both activating and inhibitory 
receptors on dNK cells (12–15). Furthermore, HLA-G modulates 
the response of different cellular subsets, including dNK, APC, 
T cells, and B cells (16, 17). The complex maternal–fetal immune 
cross-talk at the interface creates a tolerogenic niche for the nor-
mal development of the fetus, and it differs from the peripheral 
immune system of both mother and child (18). Indeed, immune 
cells can be generated locally with a different function than the 
one acquired at the periphery. For example, CD8 T cells express 
significantly lower levels of perforin and granzyme-B, and DC are 
arrested in a tolerogenic state (18, 19). Each pregnancy is charac-
terized by a unique mother–fetus HLA combination, which may 
generate different immune effector and regulatory mechanisms 
(20, 21). Maternal–fetal HLA-C mismatches (mm) induce a 
shift toward higher levels of effector and regulatory T cells in the 
decidua (20). In addition, specific combinations of maternal KIRs 
and fetal HLA-C can induce pregnancy complications (22, 23). 
Indeed, the HLA-C ligands for KIRs are divided into two groups, 
the C1 allotype binds inhibitory KIRs whereas the C2 allotype 
binds both activating and inhibitory KIRs (10, 11). Therefore, 
while KIR2DL1/HLA-C2 leads to inhibition, KIR2DS1/HLA-C2 
leads to activation of dNK (15, 24). The risk of recurrent mis-
carriage increases in women with KIR-A haplotype when they 
have fewer C2 genes than the fetus, or when the fetus inherited 
C2 from the father (18, 25). Indeed, the proper dNK activation 
is essential to facilitate trophoblast invasion and a successful 
placentation (26). Furthermore, lower levels of soluble HLA-G 
(sHLA-G) have been described in the circulation of pregnant 
women with pre-eclampsia, intrauterine growth retardation, and 
recurrent spontaneous abortion (27, 28).
With respect to CMV, the role of HLA in the local immune 
response in the placenta is largely unknown. With regard to HLA-
G, higher CMV viral loads in urine of children homozygous for 
the HLA-G 14 bp deletion were found (29). In addition, higher 
levels of sHLA-G were shown in serum and amniotic fluid of 
women with primary CMV infection and in symptomatic neo-
nates (30). The aim of this study was to determine if the combina-
tion of maternal and child HLA Ags influences the short- and 
long-term outcome of cCMV, thus providing new insights into 
cCMV immune regulation and pathogenesis. Our investigations 
focused on the role of HLA-C, HLA-E, and HLA-G, which are the 
only HLA molecules expressed at the placenta.
MaTerials anD MeThODs
study Population and clinical Data
A previously described nationwide, retrospective cohort was used 
in this study (31, 32). The cohort was derived from a total group 
of 31,484 children, born in 2008 in the Netherlands, which was 
retrospectively tested for cCMV by PCR of CMV DNA in neona-
tal dried blood spot (DBS) at 5 years of age. In total, 156 children 
(0.5%) were diagnosed with cCMV. Clinical data were retrieved 
from 125 congenitally CMV-infected children and from 263 non-
infected children. For this study, buccal swabs from 104 children 
with cCMV and their mothers were obtained for HLA-typing. 
Two buccal swabs [FLOQSwabs hDNA Free, 20-mm breaking 
point in 174.5 mm long dry tube (COPAN ITALIA SPA, Brescia, 
Italy)] were retrieved from each individual. Children were defined 
as symptomatic at birth if they had one or more of the following 
signs or symptoms in the neonatal period: prematurity, being 
small for gestational age, microcephaly, hepato- or splenomegaly, 
generalized petechiae or purpura, hypotonia, abnormal labora-
tory findings (elevated liver transaminases, hyperbilirubinemia, 
neutropenia, or thrombocytopenia), cerebral ultrasound abnor-
malities, ophthalmologic abnormalities, or neonatal hearing 
impairment. LTI was defined as the presence of impairment 
in one or more domain (hearing, visual, neurological, motor, 
cognitive, and speech-language). Because in this cohort maternal 
seroimmunity to CMV before birth was unknown, it was assumed 
that cCMV infection could have resulted from either maternal 
primary or secondary infection. This study was approved by the 
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Medical Ethics Committee of the Leiden University Medical 
Center, and all the parents of the children included have given 
written informed consent in accordance with the Declaration of 
Helsinki.
Dna extraction from DBs and qPcr of 
cMV
After a first initial CMV PCR screening performed at the National 
Institute for Public Health and the Environment (RIVM), a sec-
ond confirmatory PCR was performed at the Leiden University 
Medical Center (LUMC) (31). For this purpose, DNA was 
extracted from DBS by using the QIAamp DNA minikit according 
to the previously described protocol (33). For each test, one full 
DBS was punched by using an automated DBS puncher (1296-
071, Perkin Elmer-Wallac, Zaventem, Belgium). CMV DNA 
amplification of a 126-bp fragment from the immediate-early Ag 
region was performed using an internally controlled quantitative 
real-time PCR, as described previously (34, 35), on the CFX96 
Real-Time PCR Detection System (BioRad, Veenendaal, The 
Netherlands). The PCR was performed in triplicate, and the CMV 
viral load was expressed in IU/ml.
Dna extraction from Buccal swabs
DNA was extracted from the buccal swabs by using the QIAamp 
DNA (blood) mini kit (QIAGEN, Hilden, Germany) according 
to the manufacturer’s instruction, with an additional PBS pre-
incubation of 30 min at room temperature. In addition, the pre-
incubation fluid from two swabs was applied to one QIAamp spin 
column, in order to concentrate the DNA. The DNA was eluted in 
150 µl of Tris–EDTA-4 buffer for further analyses.
hla and Kir Typing
All mothers and children were DNA typed at low resolution for 
HLA-C locus (14 alleles) using the Reverse Sequence Specific 
Oligonucleotides PCR technique. For this purpose, a commer-
cially available assay was applied, LIFECODES C SSO Typing 
kits (Immucor, Norcross, GA, USA). Data were analyzed using 
MatchIT software (Immucor-Lifecodes). The HLA-C alleles 
included in this study were selected based on 5,604 randomly 
selected healthy Dutch blood donors who were previously geno-
typed (36). This group is considered to be a proper representation 
of the gene distribution in the general population (37), and the 
HLA-C frequencies are depicted in Table S1 in Supplementary 
Material. HLA-C allotypes were divided in two groups, namely 
HLA-C1 and HLA-C2, based on the presence of SER77ASN80 
(C1) and ASN77LYS80 (C2) at position 80 of the α1 domain, as 
previously described (38).
All mothers and children were typed for the two most com-
mon HLA-E functional alleles, HLA-E*01:01 and HLA-E*01:03 
(39). Eight different HLA-E proteins have been identified from 
26 coding sequences, but the aforementioned ones, due to their 
functional differences, are the two most commonly analyzed 
worldwide (39). Due to a non-synonymous mutation these 
two functional alleles differ in one aa position in codon 107 
of the α heavy chain, HLA-E*01:03 encoded proteins show 
higher cell surface expression and peptide-binding affinity 
than HLA-E*01:01proteins (40). Determinations of the HLA-
E*01:01/01:03 variants (SNP ID rs1264457) were carried out 
by using the TaqMan® SNP Genotyping Assays (ThermoFisher 
Scientific, MA, USA) on a ViiA™ 7 Real-Time PCR System 
(ThermoFisher Scientific, MA, USA) in a 96 well-plate using a 
thermocycling profile as follows: 10  min 95°C followed by 40 
cycles of 95°C (15 s), 60°C (1 min), and finally after cycling 60°C 
(30 s) with 1.5 µl of diluted DNA extract and 8.5 µl of reaction 
mix. Data were analyzed using ViiA™ 7 Software.
All mothers and children were typed for the HLA-G locus by 
using a TaqMan assay for the 14-bp insertion/deletion polymor-
phism in exon 8 of the 3′ untranslated region with primers and 
probes previously described (41). Nine different HLA-G proteins 
from 28 alleles have been described (42), however, the polymor-
phism included in this study is one of the most commonly asso-
ciated with pregnancy (43–47). The TaqMan assay consisted of 
1.5 µl diluted DNA extract and 15 µl reaction mixture containing: 
7.5 µl TaqMan Universal Master Mix II with UNG (ThermoFisher 
Scientific, MA, USA), 300 nM of forward and reverse primers, 
200 nM of HLAG14FAM (insertion) and HLAGdelCY5 (deletion) 
probes. The PCR was performed on a Light Cycler®96 Detection 
System (Roche Applied Science, Mannheim, Germany) in a 96 
well-plate using a thermocycling profile as follows: 10 min 95°C 
followed by 50 cycles of 95°C (10 s), 58°C (50 s) and finally after 
cycling 37°C (30  s). Data were analyzed with Light Cycler®96 
Analysis Software 1.1.
All mothers were genotyped at low resolution for KIR recep-
tors. The KIR genotype differs based on the absence of activating 
KIRs (haplotype AA) or on the presence of different numbers of 
activating KIRs (haplotype AB or BB). In particular, the BB or AB 
haplotype is defined as the presence of one or more of the follow-
ing genes: KIR2DL2, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, 
KIR2DS5, and KIR3DS1. The AA haplotype is defined by the 
absence of all the above mentioned genes and the presence of the 
following genes: KIR2DL1, KIR2DL3, KIR2DS4, and KIR3DL1. 
The KIR genotyping was performed using 11 homemade PCR 
reactions per individual, according to a previously described 
protocol (48). In each reaction, 2 µl of diluted DNA extract was 
amplified in 20 µl of SybrGreen-based PCR mix (IQ Sybr Green 
Supermix, BioRad, CA, USA) containing 0.3 pmol/μl of primers. 
The PCR was performed on a Light Cycler®96 Detection System 
(Roche Applied Science, Mannheim, Germany) in a 96 well-plate 
using a thermocycling profile as follows: 10 min at 95°C followed 
by 40 cycles of 95°C (15 s) and 62°C (60 s). Data were analyzed 
with Light Cycler®96 Software 1.1.
statistical analysis
Data were analyzed by using the Statistical Package for Social 
Sciences (SPSS, version 23, Chicago, IL, USA). The chi-square 
test was used to evaluate the observed and expected genotypes 
frequency, the number of HLA mm, missing-self (ms), non-
inherited maternal antigens (NIMAs), and the combinations 
between maternal KIR with child HLA-C, in relation to symptoms 
at birth and LTI. With expected low values, a Fischer’s exact test 
was used instead. The maternal and fetal HLA allele frequencies 
were tested for Hardy–Weinberg equilibrium (HWE), stating 
that in the absence of other influences the genotype frequency 
TaBle 1 | Characteristics and clinical outcome of study population.
congenital cMV infection
Overall asympt.a sympt.b
 n = 96 n = 77 n = 19
gender
Male 57 44 13
Female 39 33 6
gestational age (weeks)c 39 (28–42) 39 (37–42) 36 (28–41)







Hearing impairmentd 3 2 1
Visual impairmente 2 2 0
Neurological impairmentf 5 2 3
Motor impairmentg 13 9 4
Cognitive impairmenth 7 4 3
Speech/language problemi 18 10 8
One or more impairmentj 27 16 11
aAsymptomatic at birth.
bSymptomatic at birth: premature (n = 11), dysmature (n = 2); microcephaly (n = 5); 
neonatal hearing loss (n = 1); abnormal cranial ultrasound (n = 1).
cValues are medians with minimum and maximum.
dSensorineural hearing loss.
eOptic nerve atrophy (n = 1), cortical visual impairment (n = 1).
fCerebral palsy (n = 1), epilepsy (n = 1), microcephaly (n = 1), ADHD (n = 1), autism 
(n = 3).
gMotor impairment (fine, gross, or balance) based on test or diagnosis or sensory 
processing disorder or developmental coordination disorder.
hCognitive impairment based on test or diagnosis.
iLanguage impairment based on test or diagnosis, speech-impairment, oral motor skill 
difficulties, or auditory processing disorder.
jAny long-term impairment, in one or more domains.
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in a certain population remains constant from generation to 
generation (49). In addition, a univariate logistic regression 
was performed to investigate potential predictors of symptoms 
at birth and LTI development. A p-value <0.05 was considered 
statistically significant.
resUlTs
study Population and clinical Data
The clinical data of the congenitally infected children included in 
this study are depicted in Table 1. A total of 96 mother–child pairs 
were successfully typed for at least one of the HLA genes included 
in this study. Eight mother–child pairs could not be typed due 
to low DNA quality and concentration. Nineteen (20%) children 
had symptoms at birth, and 11 (58%) of those had LTI. In addi-
tion, 16 (21%) asymptomatic children had LTI. Overall, 27 (28%) 
of infected children developed any LTI.
Maternal and child hla-c, hla-e, and 
hla-g genotypes in relation to ccMV 
clinical Outcome
First, we evaluated whether the maternal genotype plays a role 
in cCMV outcome. For this purpose, we tested whether the 
genotype frequencies of the HLA-C groups, C1 and C2, and of 
the HLA-E and HLA-G alleles from the mothers were in HWE. 
The HLA-C groups of mothers with children symptomatic at 
birth were not in HWE (p = 0.046) (Table S2 in Supplementary 
Material). In our cohort, a significantly higher percentage of 
mothers was homozygous for HLA-C1 in the group of children 
symptomatic at birth compared to the asymptomatic group, 
whereas the percentage of mothers homozygous or heterozy-
gous for HLA-C2 was lower (Table 2). The functional difference 
between HLA-C1 and HLA-C2 suggests a possible association 
of these alleles with clinical outcome in our cohort (23, 50, 51), 
with absence of maternal HLA-C2 being a risk factor. Indeed, 
the odds of having symptomatic neonates was higher when 
mothers were homozygous for HLA-C1 than when mothers 
were homozygous for HLA-C2 or heterozygous (OR = 3.950, 
95% CI 1.378–11.320, p = 0.011). Consequently, only 5.3% of 
children symptomatic at birth were homozygous for HLA-C2 
(Table 2).
The genotype frequencies of HLA-E and HLA-G alleles 
from the mothers were in HWE in all groups (Table S2 in 
Supplementary Material). Despite this, a significantly higher 
percentage of mothers homozygous for HLA-G deletion 
(HLA-G del/del) was observed in the group of children that 
developed LTI compared to those who did not; this percent-
age was also higher in the symptomatic group compared to 
the asymptomatic group, though not significant (Table  3). 
HLA-G del/del is related to higher HLA-G protein levels 
(52, 53), soluble and possibly membrane-bound; therefore, 
our findings suggest that the functional difference of the two 
alleles is associated with clinical outcome, with the maternal 
homozygous status being a risk factor. Indeed, the odds of 
developing LTI was higher when mothers were HLA-G del/del 
(OR 3.542, 95% CI 1.397–8.977, p = 0.008). Likewise, the odds 
of having symptoms at birth were higher when mothers were 
HLA-G del/del, although not significant (not shown). Next, 
given the role of HLA-G during CMV infection, the HLA-G 
del/del polymorphism was assessed in relation to CMV viral 
load. For this purpose, the study group was divided into two 
groups according to the viral load measured in DBS namely 
low (< 500 IU/ml) and high (> 500 IU/ml) viral load groups. A 
higher percentage of mothers with HLA-G del/del was observed 
in the high viral load group compared to the low viral load 
group (41.4 and 12.0%, respectively, p = 0.008), whereas this 
was not observed in the children (30.0 and 32.0% respectively, 
p = 0.852) (Table S3 in Supplementary Material).
Finally, we evaluated whether the child’s genotype plays a 
role in cCMV outcome. The genotype frequencies of the HLA-C 
groups, and HLA-G alleles in the children were in HWE in all 
groups, whereas the HLA-E alleles were not, both in the symp-
tomatic and asymptomatic groups (p  =  0.037 and p  =  0.024, 
respectively) (Table S2 in Supplementary Material). A higher 
percentage of children heterozygous for HLA-E was observed 
in the symptomatic group compared to the asymptomatic group 
whereas the percentage of homozygotes, either HLA-E*0101 or 
HLA-E*0103, was lower (Table  4). HLA-E*0103 is associated 
with higher protein levels (40); therefore, our findings suggest 
that the functional difference of the two alleles is not associated 
with clinical outcome.
TaBle 2 | HLA-C, KIR, and congenital CMV infection (cCMV) clinical outcome.
 symptoms at birth long-term impairments (lTi)
symptomatic %  
(n = 19)




lTi (≥1)a %  
(n = 26)






C1C2 21.1 52.6 38.5 49.3
C1C1 63.2 30.3 30.8 39.1
C2C2 15.8 17.1 30.8 11.6
Child 0.371 0.712
C1C2 52.6 46.1 50 46.4
C1C1 42.1 35.5 30.8 39.1
C2C2 5.3 18.4 19.2 14.5
HLA-C mmc 84.2 68.4 0.172 80.8 68.1 0.223
HLA-C1 mmd 15.8 11.8 0.701k 19.2 10.1 0.300k
HLA-C2 mme 31.6 10.5 0.031k* 19.2 13 0.519k
HLA-C msf 78.9 72.4 0.560 96.2 65.2 0.002*
HLA-C1 msg 5.3 13.2 0.454k 7.7 13 0.722k
HLA-C2 msh 10.5 18.4 0.514k 19.2 15.9 0.761k
Kir haplotype motheri 0.659 0.356
A 36.8 31.5 40 29.9
B 63.2 68.5 60 70.1
Maternal KIR A–Child C2j 21.1 20.5 1.000k 20 20.9 0.925
aAny long-term impairment, in one or more domains of impairments: hearing, visual, neurologic, motor, cognitive, and speech-language.
bAbsence of any long-term impairment.
cHLA-C mm: HLA-C mismatches (mm).
dHLA-C1 mm: HLA-C mm in the C1 group, the mother is homozygous for C2 and the child is heterozygous.
eHLA-C2 mm: HLA-C mm in the C2 group, the mother is homozygous for C1 and the child is heterozygous.
fHLA-C ms: HLA-C missing-self.
gHLA-C1 ms: HLA-C missing-self in the C1 group, the mother is heterozygous and the child is homozygous for HLA-C2.
hHLA-C2 ms: HLA-C missing-self in the C2 group, the mother is heterozygous and the child is homozygous for HLA-C1.
iMaternal KIR A haplotype is defined as the absence of activating KIRs (AA) and KIR B haplotype as the presence of different numbers of  
activating KIRs (AB or BB).
jCombination of maternal KIR A haplotype with HLA-C2 positive child (either C1C2 or C2C2); i,jN asymptomatic = 73, N  
with LTI = 25, N without LTI = 67.
kFischer’s exact test used.
*p < 0.05.
TaBle 3 | HLA-G and congenital CMV infection (cCMV) clinical outcome.
 symptoms at birth long-term impairments (lTi)
 symptomatic %  
(n = 19)




lTi (≥1)a %  
(n = 27)






del/del 52.6 29.9 55.6 26.1
ins/ins 10.5 15.6 11.1 15.9
del/ins 36.8 54.5 33.3 58
Child 0.459 0.514
del/del 26.3 32.5 37 29
ins/ins 10.5 19.5 11.1 20.3
del/ins 63.2 48.1 51.9 50.7
HLA-G del mmc 5.3 10.4 0.683j 3.7 11.6 0.437j
HLA-G ins mmd 31.6 11.7 0.070j 25.9 11.6 0.116j
HLA-G del mse 5.3 14.3 0.449j 3.7 15.9 0.169j
HLA-G ins msf 5.3 14.3 0.449j 7.4 14.5 0.500j
aAny long-term impairment, in one or more domains of impairments: hearing, visual, neurologic, motor, cognitive, and speech-language.
bAbsence of any long-term impairment.
cHLA-G del mm: HLA-G deletion mismatches (mm), the mother is homozygous for HLA-G insertion and the child is heterozygous.
dHLA-G ins mm: HLA-G insertion mm, the mother is homozygous for HLA-G deletion and the child is heterozygous.
eHLA-G del ms: HLA-G deletion missing-self, the mother is heterozygous and the child is homozygous for HLA-G insertion.
fHLA-G ins ms: HLA-G insertion missing-self, the mother is heterozygous and the child is homozygous for HLA-G deletion.
jFischer’s exact test used.
*p < 0.05.
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TaBle 5 | Definitions: mismatches (mm), missing-self (ms), and non-inherited 
maternal antigens (NIMAs).













a/b a/a No Yes Yes
a/b b/b No Yes Yes
a/b a/c Yes Yes Yes
a/b c/b Yes Yes Yes
a/a a/b Yes No No
b/b a/b Yes No No
a/a a/a No No No
a/b a/b No No No
b/b b/b No No No
aCombinations of maternal and child HLA genotype by using 3 hypothetical genes  
(a, b, c).
bmm are defined as the antigen (Ag) that the child has but the mother does not have, 
because the inherited paternal antigen (IPA) is different from both  
maternal alleles.
cMissing-self (ms) is defined as the Ag that the mother has and the child does not 
because the inherited paternal antigen (IPA) differs from the non-inherited maternal 
antigen (NIMAs).
dNIMAs are defined as the Ag that the child did not inherit but is exposed to, due to 
maternal microchimerism.
TaBle 4 | HLA-E and congenital CMV infection (cCMV) clinical outcome.
symptoms at birth long-term impairments (lTi)
 symptomatic %  
(n = 19)




lTi (≥1)a %  
(n = 26)






0101/0101 21.1 27.6 23.1 27.5
0103/0103 36.8 23.7 30.8 24.6
0101/0103 42.1 48.7 46.2 47.8
Childg 0.015* 0.714
0101/0101 15.8 35.5 33.3 30.9
0103/0103 10.5 27.6 18.5 26.5
0101/0103 73.7 36.8 48.1 42.6
HLA-E*0101 mmc 36.8 11.8 0.016h* 26.9 13 0.129h
HLA-E*0103 mmd 15.8 9.2 0.413h 15.4 8.7 0.453h
HLA-E*0101 mse 10.5 17.1 0.728h 15.4 15.9 1.000h
HLA-E*0103 msf 10.5 17.1 0.728h 23.1 13 0.343h
aAny long-term impairment, in one or more domains of impairments: hearing, visual, neurologic, motor, cognitive, and speech-language.
bAbsence of any long-term impairments.
cHLA-E*0101 mm: HLA-E*0101 mismatches (mm), the mother is homozygous for HLA-E*0103 and the child is heterozygous.
dHLA-E*0103 mm: HLA-E*0103 mm, the mother homozygous for HLA-E*0101 and the child is heterozygous.
eHLA-E*0101 ms: HLA-E*0101 missing-self, the mother is heterozygous and the child is homozygous for HLA-E*0103.
fHLA-E*0103 ms: HLA-E*0103 missing-self, the mother is heterozygous and the child is homozygous for HLA-E*0101.
gN = 27 neonates with LTI and N = 68 neonates without LTI.
hFischer’s exact test used.
* p < 0.05.
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Maternal–Fetal hla-c, hla-e, and hla-g 
mm in relation to ccMV clinical Outcome
We next investigated whether maternal–fetal HLA mm are asso-
ciated with a worse cCMV outcome. For this purpose, mm were 
calculated on the basis of the presence of an Ag in the fetus, which 
was absent in the mother because the inherited paternal antigen 
(IPA) was different from both maternal alleles (Table 5). The mm 
were compared between children symptomatic and asympto-
matic at birth, as well as between children who developed LTI and 
those who did not. A significantly higher percentage of HLA-C2 
mm was observed in the symptomatic group compared to the 
asymptomatic group (Table 2). Most likely, the mm derived from 
the higher percentage of mothers homozygous for HLA-C1 while 
a higher percentage of symptomatic neonates was heterozygous 
(Table  2). Therefore, the functional consequence of HLA-C2 
absence in the mother might be the main risk factor, even though 
the odds of having symptoms at birth were significantly higher 
as well with HLA-C2 mm (OR =  3.923, 95% CI 1.166–13.201, 
p = 0.027).
To exclude the possibility that symptoms at birth were associ-
ated with specific HLA-C KIR combinations rather than maternal 
genotypes or maternal–fetal mm, the number of HLA-C1/HLA-
C2 KIR epitope combinations were analyzed. No differences 
in preferential fetal HLA-C/maternal KIR combinations were 
observed (Table 2). In addition, a significantly higher percentage 
of HLA-E*0101  mm was observed in the symptomatic group 
compared to the asymptomatic (Table 4). The HLA-E mm may 
be driven by the neonatal aberrant distribution of the genotypes. 
However, because the difference in HLA-E genotypes would 
probably have no functional consequences, the mm may be the 
primary risk factor. Indeed, the odds of developing symptoms 
at birth were significantly higher when HLA-E*0101 mm were 
present (OR = 4.343, 95% CI 1.357–13.897, p = 0.013). In addi-
tion, the HLA-E*0101  mm was assessed in relation to CMV 
viral load, and a higher percentage of HLA-E*0101  mm was 
found in the high viral load group compared to the low viral 
load group (23.2% and 0.0% respectively, p = 0.005) (Table S3 in 
Supplementary Material). Finally, no differences in HLA-G mm 
were observed with respect to symptoms nor to LTI development 
(Table 3).
FigUre 1 | Placental CMV infection according to maternal HLA-G genotype. (a) Mothers homozygous for HLA-G deletion are predisposed to having higher levels 
of soluble HLA-G (sHLA-G), and possibly membrane-bound HLA-G, proteins in those tissues where HLA-G is expressed, such as endothelial cells and monocytes/
macrophages. When maternal T cells encounter an infected cell with higher levels of HLA-G, it is inhibited. This creates a favorable environment for CMV replication 
and dissemination. Consequently, more extensive infection of the placenta leads to increased CPE, inflammation, thickening, and dysfunction. This, in turn, 
contributes to a worse outcome. (B) Mothers homozygous for HLA-G insertion, or heterozygous, are predisposed to having lower levels of sHLA-G, and possibly 
membrane-bound HLA-G, proteins. When maternal T cells encounter an infected cell with lower levels of HLA-G protein, it is activated. CMV replication and 
dissemination is, therefore, contained. Consequently, lower numbers of infected cells and viral loads reach the placenta, with a reduced CPE, inflammation, 
thickening, and dysfunction. This in turn contributes to a better outcome.
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hla-c, hla-e, and hla-g Missing-self/
niMas in relation to ccMV clinical 
Outcome
We finally assessed whether missing-self/NIMAs influence cCMV 
clinical outcome. For this purpose, missing-self was defined as 
an Ag in the mother, which was absent in the child because the 
IPA was different from the NIMA (Table 5). From the mothers’ 
perspective, missing-self implies a mechanism of recognition by 
dNK of trophoblasts lacking maternal self-molecules. Missing-
self does not necessarily indicate mm because the IPA could still 
be the same as the inherited maternal Ag (Table 5). The maternal 
Ag, which was missing in the child, is considered by the child 
a NIMA. Therefore, despite being the same aforementioned Ag, 
other mechanisms than recognition by dNK of missing-self are in 
place. Hence, we will refer to this Ag, triggering different responses, 
as missing-self/NIMAs. In our cohort, there were no significant 
differences in HLA-C, HLA-E, and HLA-G missing-self/NIMAs 
in relation to symptoms at birth. However, for LTI development, 
a significantly higher percentage of HLA-C missing-self/NIMAs, 
but not of HLA-E and HLA-G missing-self/NIMAs, was observed 
(Tables 2–4). The aforementioned results suggest that the HLA-C 
missing-self/NIMA may be considered as a risk factor for LTI 
development, rather than for symptoms at birth. Indeed, the odds 
of developing LTI was significantly higher when the child had 
HLA-C mismatched NIMAs (OR 13.3, 95% CI 1.701–104.535, 
p = 0.014).
DiscUssiOn
To gain more insights into cCMV pathogenesis and its clinical 
consequences, the role of HLA-C, HLA-E, and HLA-G genotypes 
was evaluated in a large cohort of children with cCMV and 
their mothers. HLA-C, HLA-E, and HLA-G are the only HLA 
molecules expressed by the trophoblasts and, therefore, they 
might play a role in cCMV outcome. To systematically discuss 
the findings, they will be described in relation to the compart-
ments involved in the virus–host interaction, which are maternal, 
placental, fetal, and child.
First of all, the nature of maternal infection and her immune 
response can influence cCMV outcome. In our cohort, the mater-
nal HLA-G del/del genotype was associated with a worse cCMV 
outcome. This could be explained by the immunosuppressive 
effect of this genotype which is associated with the presence of 
higher HLA-G protein levels, soluble and possibly membrane-
bound (52, 53). Indeed, HLA-G can inhibit various immune cell 
subsets (16, 17). The hypothetical model to account for maternal 
HLA-G genotype in relation to cCMV outcome is depicted in 
Figure 1. In addition, CMV induces upregulation of HLA-G in 
FigUre 2 | Placental immunopathology. (a) Viral infections can increase the levels of pro-inflammatory cytokines and chemokines and increase the influx of T cells 
in decidual tissues (60, 61). (B) The regulatory mechanisms might not be able to efficiently modulate the maternal fetus-specific lymphocytes, specific for HLA-C and 
HLA-E, which can, therefore, directly or indirectly recognize trophoblast cells. (c) HLA-C and HLA-E mismatches (mm) could prevent an optimal viral clearance 
because maternal CMV-specific cells would not efficiently recognize CMV presented in the context of allo-HLA. (D) In the absence of maternal HLA-C2, the balance 
between activating and inhibitory signals on dNK cells may be more skewed toward dNK cells activation, because HLA-C1 has less inhibitory capacity on dNK. This 
activation could in turn promote a pro-inflammatory response, exacerbating placental immunopathology.
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order to escape the host defense and, after an initial local replica-
tion, CMV dissemination is likely to be cell-associated, occurring 
mainly through endothelial and monocytes/macrophages (54). 
Hence, higher HLA-G protein levels might create a favorable 
environment for CMV, facilitating replication and dissemination. 
Interestingly, this HLA-G del/del polymorphism has been associ-
ated with active CMV infection with higher viral loads in children 
(29). In our cohort, maternal samples during pregnancy were not 
available. However, neonatal CMV viral load determined in DBS 
was related to the HLA-G genotype of the mother, as reflected 
by the higher percentage of mothers HLA-G del/del in the high 
viral load group compared to the low viral load group (Table S3 in 
Supplementary Material). This suggests that a reduced maternal 
control of CMV infection may increase the viral loads at the 
placenta and, consequently, in the fetus. Placental CMV infection 
triggers an inflammatory response that alters the trophoblast, 
inducing placental dysfunction and fetal impairments, such as 
intrauterine growth retardation (55–57). Interestingly, in a group 
of pregnant women with primary CMV infection and neonates 
with CMV disease, the placental thickness was increased (58). 
In addition, in another cohort of pregnant women with primary 
CMV infection, increased sHLA-G levels were observed in both 
maternal serum and amniotic fluid of symptomatic fetuses (30). 
However, no information was available on the maternal and child 
HLA-G genotypes.
Vertical transmission occurs through placental infection, 
which therefore was considered after the maternal immune 
response. The hypothetical model to account for our findings in 
the placenta in relation to cCMV outcome is shown in Figure 2. 
First of all, a significantly higher percentage of symptomatic neo-
nates had HLA-E*0101 mm, and a higher extent of HLA-C mm. 
HLA mm have been shown to result in the occurrence of maternal 
fetus-specific T cells, both in the maternal peripheral blood and at 
the maternal–fetal interface (20, 59). In normal conditions, this 
does not impair pregnancy because there is a parallel increase 
of regulatory mechanisms modulating such responses (20). 
However, viral infections can increase the levels of pro-inflamma-
tory cytokines, chemokines, and the influx of T cells in decidual 
tissues (60, 61). In this situation, the regulatory mechanisms 
might not be able to efficiently inhibit allogeneic lymphocytes 
(19), which could damage the placenta. Furthermore, because 
CMV peptides can be presented in the context of HLA-C and 
HLA-E (62–64), mm could lead to suboptimal viral clearance at 
the placenta, as maternal CMV-specific cells would not efficiently 
recognize CMV presented in the context of allo-HLA. This has 
been described in allogeneic hematopoietic stem cell transplanta-
tion, where the clinical activity of donor-derived virus-specific 
T  cells can be abolished if the immunodominant T  cells are 
restricted by HLA not shared by the host (65). Consequently, 
this may result in higher placental and fetal viral loads. Indeed, a 
higher percentage of maternal–fetal HLA-E*0101 mm was found 
in the high viral load group compared to the low viral load group, 
and the same was observed for HLA-C mm (76.8 and 56.0% 
respectively, p  =  0.049) (Table S3 in Supplementary Material). 
Finally, dNK cells are the predominant leukocyte population at 
the placenta, and they play a central role in the immune cross-talk 
FigUre 3 | Non-inherited maternal antigen (NIMA) effect and linked immunosuppression in congenital CMV infection long-term outcome. (a) During pregnancy, 
maternal cells pass through the placenta to the fetus and can engraft in several fetal tissues, which may be infected by CMV, and persist at least till adulthood. 
Maternal cells can be either CMV infected or not, and can carry HLA Ags that the child does not have, i.e., NIMAs. (B) After NIMAs recognition by fetal T cells, 
tolerogenic APCs, with reduced T cell-activating capacity, are induced in order to suppress a fetal antimaternal immune response. These tolerogenic APCs may be 
also specific for CMV, as maternal cells can be infected or can reside in infected fetal tissues, and suppress CMV-specific T cells (linked immunosuppression). (c) 
The antiviral response in the child is therefore less efficient, possibly leading to a more persistent viral replication with a chronic productive infection, and tissue 
damage.
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and in the placentation process. The combination of maternal 
AA KIR with fetal HLA-C2 was associated with increased risk 
of pre-eclampsia, as it led to the absence of activated dNK and 
poor placentation (23). Indeed, HLA-C2 has a stronger inhibition 
capacity when binding to its inhibitory KIR (KIR2DL1) than C1 
with its corresponding receptor (KIR2DL2/3) (23, 50, 51). In 
our cohort, clinical outcome was not associated with specific 
maternal KIR-fetal HLA-C combinations. Rather, the absence of 
maternal HLA-C belonging to the C2 group was associated with 
a worse cCMV outcome at birth. In the absence of HLA-C2, the 
activating signals on dNK cells may prevail the inhibitory signals, 
which in turn promote a pro-inflammatory response. In addition, 
it has been shown that expression of KIR2DS1 by dNK increases 
their cytotoxic function toward infected maternal decidual stro-
mal cells, which could possibly lead to a reduction of placental 
virus-induced pathology (24). In our cohort, the presence of the 
maternal gene KIR2DS1 was not associated with a better short- 
and long-term outcome (Table S4 in Supplementary Material). 
However, these results would need to be confirmed as the lack 
of statistical power may have been a limiting factor in detecting 
a small effect. Taken together, the aforementioned mechanisms 
may contribute to the complex multifactorial process of placental 
immunopathology and dysfunction, which has a direct impact 
on outcome at birth. Importantly, besides the fact that placental 
inflammation has been described in relation to cCMV (55–57), 
prematurity has also been associated with chronic placental 
inflammation in the absence of infections (66). Given the rela-
tively high percentage of premature infants with cCMV in our 
cohort, we evaluated whether the aforementioned markers shown 
to be associated with symptoms may have been influenced by 
this. After excluding the 11 premature infants, a slight change in 
p-values, but with the same trend of percentages, was observed in 
relation to symptoms at birth (data not shown), most likely due 
to the lack of statistical power. This suggests that we cannot fully 
exclude that the relatively high percentage of premature infants 
in the symptomatic group partially influenced the association 
between the aforementioned biomarkers and symptoms. Taking 
into account the association between cCMV and prematurity 
(67), it may be plausible to assume that prematurity is an effect of 
both cCMV and the aforementioned HLAs.
The child’s immune response was considered after the pla-
cental compartment, and the hypothetical model to account for 
our findings in relation to cCMV outcome is shown in Figure 3. 
Although certain cCMV clinical consequences are present 
directly after birth, some of the permanent impairments have an 
onset in the first years after birth, or may progress during child-
hood (1). The late-onset hearing loss is commonly considered as 
the result of a chronic disease syndrome, of which the molecular 
mechanisms have not been elucidated yet, though data suggest 
that they are due to a chronic productive infection throughout 
childhood (7, 8). For this reason, the child’s immune response to 
CMV may play a central role in preventing LTI. In our cohort, a 
high percentage of children with LTI had maternal–fetal HLA-C 
NIMAs. Their role in LTI development may lie in the tolerance 
induced in the fetus toward NIMAs. Indeed, during pregnancy 
and after birth, the child is exposed to maternal allogeneic cells 
because of the transfer of maternal cells to the fetus, namely 
maternal microchimerism (68, 69). The developing neonatal 
immune system does not consider NIMAs as non-self, but rather 
develops long-lasting regulatory mechanisms to prevent an 
immune response against NIMAs. The NIMA effect has mainly 
been shown in transplantation. The survival rate of kidney grafts 
with a mismatched Ag identical to the recipient’s NIMA was 
better than in  situations where the mismatched Ag was not a 
NIMA (70, 71). Similar effects have been shown in case of stem 
cell, cord blood, and bone marrow transplantation (72–74). Fetal 
T cells can recognize NIMAs presented by maternal cells via the 
shared HLA, or by fetal APC in the context of HLA class I and 
class II. One of the first steps in the tolerance toward NIMAs is 
the induction of NIMA-specific Tregs, which suppress the fetal 
antimaternal immunoresponse and persist at least till early adult-
hood (75, 76). In addition, tolerogenic APCs presenting NIMAs 
are induced, and suppress NIMAs-specific T cells (77, 78). These 
mechanisms may influence the child’s immune response. First, 
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the NIMA-specific Tregs may create a general tolerogenic envi-
ronment that indirectly impair the immune response to CMV. 
Second, through a mechanism called linked immunosuppres-
sion, a certain level of tolerance specific for CMV can be induced 
(78). Indeed, fetal APCs could present both NIMAs and CMV 
Ag, as maternal cells can be infected or because maternal cells 
reside in infected fetal tissues. This may result in a less efficient 
antiviral response during childhood, which possibly leads to a 
more persistent viral replication and tissue damage. Therefore, 
while the NIMA effect may be beneficial in transplantation, it 
could prevent an optimal antiviral response due to a partial toler-
ance to CMV as well. Similar to symptoms at birth, we evaluated 
whether the relatively high percentage of premature infants in 
the symptomatic group may have influenced the results relative 
to LTI. After excluding the premature infants, the results and 
significance did not change (data not shown), suggesting that the 
relatively high percentage of premature does not influence the 
association between HLA-C NIMAs and LTI development.
This study is not without limitations. First of all, potential 
effects of CMV on the expression of the studied HLA Ags 
could not be taken into account. Indeed, CMV has developed 
strategies to evade host immunity and to establish latency, e.g., by 
down-regulating classical HLA molecules and upregulating non-
classical HLA (54, 79–81). Second, a CMV-independent role of 
these HLA combinations in adverse pregnancy outcome cannot 
be totally excluded. However, we did not observe the previously 
described HLA KIR combinations associated with pregnancy 
complications, further suggesting that our observations specifi-
cally apply to cCMV.
To the best of our knowledge, this is the first study on mater-
nal–fetal HLA in a large cohort of children with cCMV. If our 
hypotheses are correct, symptoms at birth are mainly caused 
by the immunopathology that takes place at the maternal–fetal 
interface, as a result of a multifactorial process of suboptimal viral 
clearance, enhanced allo-reactivity, and increased inflammation. 
Whereas the inefficient long-term control of CMV infection, 
which plays a role in LTI development, might have been partially 
caused by the NIMA effect. This study gives useful insights and 
generates new hypotheses on cCMV pathogenesis in all compart-
ments involved during cCMV. Furthermore, if confirmed in other 
cohorts, these findings could be evaluated as potential prognostic 
markers for clinical outcome. Indeed, a reliable marker for cCMV 
outcome could provide the means to introduce the long-debated 
newborn screening program for CMV in DBS by defining sub-
groups of neonates that would benefit from clinical, audiological 
follow-up, and possibly antiviral treatment (82).
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